Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-003 in Healthy Postmenopausal Women
NCT07118085Phase 1Recruiting
- Sponsor
- ImmuneOnco
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Fc-fusion protein, Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoporosis comparing IMC-003 with placebo for IMC-003 (2 arms). Primary endpoint: Incidence and severity of adverse events and serious adverse events at 12 weeks. Started Aug 2025; status: recruiting.
02
Drugs
IMC-003
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT07118085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118085.